Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond

Area of Science:

• Oncology
• Pharmacology

Background:

• Extensive-stage small-cell lung cancer (ES-SCLC) has a poor prognosis despite current treatments.
• Limited second-line treatment options exist for ES-SCLC.
• Chemo-immunotherapy has not significantly improved survival outcomes.

Purpose of the Study:

• To review the clinical data of antibody-drug conjugates (ADCs) for ES-SCLC.
• To discuss ADC target biology, molecular design, and safety profiles.
• To evaluate combination strategies and future directions for ADC therapy in ES-SCLC.

Main Methods:

• Narrative review of preliminary clinical data on ADCs.
• Emphasis on target antigens (DLL3, TROP2, B7-H3, SEZ6, CEACAM5, PTK7).
• Evaluation of combination strategies and sequencing with other therapies.

Main Results:

• ADCs targeting various antigens demonstrate encouraging antitumour activity in second- and later-line settings.
• Challenges include primary and acquired resistance, and limitations in biomarkers.
• Preliminary data on safety profiles and CNS penetration are emerging.

Conclusions:

• ADCs represent a promising therapeutic class for ES-SCLC, with several agents in clinical development.
• Overcoming resistance and improving patient selection through biomarkers are critical for effective implementation.
• Combination strategies and optimal sequencing with other therapies require further investigation.